ArticleFuture oncology (London, England)2025

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.

John H Strickler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.